. Author manuscript; available in PMC: 2020 Jun 1.

Published in final edited form as: J Biomed Inform. 2019 Apr 20;94:103184. doi: 10.1016/j.jbi.2019.103184

Table 1.

Risk Classification Groups and Inclusion Criteria by Prostate Cancer Clinical Guidelines.

Guidelines	Risk group	Criteria	Number of patients
NCCN	High risk	Cancer stage T3 or T4	1047
		Gleason score ≥ 8
		Cancer stage T2 and PSA > 10 ng/mL
		Cancer stage T1 and PSA > 20 ng/mL
	Low risk	T2 and PSA ≤ 10 and Gleason < 8	1168
	Low risk	T1 and PSA ≤ 20 and Gleason < 8	1168
AUA	High risk	Cancer stage T3 or T4	989
		Gleason Grade Group 4 or Grade Group 5
		PSA > 20 ng/mL
	Intermediate unfavorable risk	Gleason Grade Group 3	510
		Gleason Grade Group 2 and 10 ≤ PSA < 20
		Cancer stage T2B or T2C and Grade Group 2
	Intermediate favorable risk	Gleason Grade Group 2 and PSA < 10	559
	Intermediate favorable risk	Gleason Grade Group 1 and 10 ≤ PSA < 20	559
	Low risk	Cancer stage T1 or T2A and Gleason Grade Group 1 and PSA < 10	469